Supports nationwide COVID-19 testing efforts; aims to increase access to accurate and reliable COVID-19 tests including at-home tests

If your email program has trouble displaying this email, view as a webpage. FDA Updates COVID-19 Test Policies  Today, the U.S. Food and Drug Administration is taking several important actions intended to support ongoing nationwide COVID-19 testing efforts. These actions are aimed at further increasing access to accurate and reliable tests, particularly COVID-19 diagnostic tests that can be performed at home or in places like doctor's offices, hospitals, urgent care centers, and emergency rooms without having to be sent to a central lab for testing. Read More The FDA: Reissued the Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised). Issued a new Umbrella EUA for SARS-CoV-2 Molecular Diagnostic Tests developed by laboratories for Serial Testing. Reissued the EUA for Molecular Diagnostic Tests for SARS-CoV-2 Developed And Performed By Laboratories Certified Under CLIA To Perform High Complexity Tests. Revised the Enforcement Policy for Viral Transport Media During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency to update references to the Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency. Updated the FAQs on Testing for SARS-CoV-2. Questions? If you have questions, please email COVID19DX@fda.hhs.gov

Follow us on Twitter at @FDADeviceInfo Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA